WallStreetZenWallStreetZen

NASDAQ: APGE
Apogee Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for APGE

Based on 2 analysts offering 12 month price targets for Apogee Therapeutics Inc.
Min Forecast
$43.00+23.17%
Avg Forecast
$43.50+24.61%
Max Forecast
$44.00+26.04%

Should I buy or sell APGE stock?

Based on 2 analysts offering ratings for Apogee Therapeutics Inc.
Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their APGE stock forecasts and price targets.

APGE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-01-03Find Out Why
lockedlocked$00.00+00.00%2023-12-20

1 of 1

Forecast return on equity

Is APGE forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is APGE forecast to generate an efficient return on assets?
Insufficient data to display

APGE revenue forecast

What is APGE's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$175.0M
Avg 2 year Forecast
$321.0M
Avg 3 year Forecast
$544.0M

APGE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
APGE$34.91$43.50+24.61%Strong Buy
MORF$35.30$43.67+23.70%Buy
AMAM$27.94$23.29-16.66%Buy
RCUS$19.53$37.43+91.65%Strong Buy
CLDX$37.75$53.00+40.40%Buy

Apogee Therapeutics Stock Forecast FAQ

Is Apogee Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: APGE) stock is to Strong Buy APGE stock.

Out of 2 analysts, 2 (100%) are recommending APGE as a Strong Buy, 0 (0%) are recommending APGE as a Buy, 0 (0%) are recommending APGE as a Hold, 0 (0%) are recommending APGE as a Sell, and 0 (0%) are recommending APGE as a Strong Sell.

If you're new to stock investing, here's how to buy Apogee Therapeutics stock.

What is APGE's revenue growth forecast for 2027-2029?

(NASDAQ: APGE) Apogee Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 52.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.01%.

Apogee Therapeutics's revenue in 2024 is N/A.On average, 1 Wall Street analysts forecast APGE's revenue for 2027 to be $8,868,001,800, with the lowest APGE revenue forecast at $8,868,001,800, and the highest APGE revenue forecast at $8,868,001,800. On average, 1 Wall Street analysts forecast APGE's revenue for 2028 to be $16,266,449,016, with the lowest APGE revenue forecast at $16,266,449,016, and the highest APGE revenue forecast at $16,266,449,016.

In 2029, APGE is forecast to generate $27,566,817,024 in revenue, with the lowest revenue forecast at $27,566,817,024 and the highest revenue forecast at $27,566,817,024.

What is APGE's forecast return on assets (ROA) for 2027-2027?

(NASDAQ: APGE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is APGE's Price Target?

According to 2 Wall Street analysts that have issued a 1 year APGE price target, the average APGE price target is $43.50, with the highest APGE stock price forecast at $44.00 and the lowest APGE stock price forecast at $43.00.

On average, Wall Street analysts predict that Apogee Therapeutics's share price could reach $43.50 by Jan 3, 2025. The average Apogee Therapeutics stock price prediction forecasts a potential upside of 24.61% from the current APGE share price of $34.91.

What is APGE's forecast return on equity (ROE) for 2027-2027?

(NASDAQ: APGE) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.